Advertisement

Tumor Biology

, Volume 35, Issue 2, pp 1331–1334 | Cite as

Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer

  • Jiuchang Xiao
  • Xiaoyan He
  • Zengyan Wang
  • Jiying Hu
  • Fang Sun
  • Feng Qi
  • Shugang Yang
  • Zhenyu Xiao
Research Article

Abstract

Previous studies have assessed the prognostic role of serum carbohydrate antigen 19-9 (CA 19-9) concentration in patients with gastric cancer, but the findings from those studies were inconsistent. We searched the PubMed and Web of Science databases to find eligible studies assessing the prognostic role of CA 19-9 in patients with gastric cancer. Twelve studies with a total of 5,072 gastric cancer patients were finally included into the meta-analysis. The pooled hazard ratio (HR) with corresponding 95 % confidence interval (95 % CI) for overall survival were calculated to assess the prognostic role of CA 19-9 in patients with gastric cancer. Overall, elevated serum concentration of CA 19-9 (>37 U/mL) was associated with poorer overall survival in patients with gastric cancer (fixed-effects HR = 1.36, 95 % CI 1.24–1.48, P < 0.001). Subgroup analysis by study design further showed that elevated serum concentration of CA 19-9 was associated with poorer overall survival in patients with gastric cancer. There was no obvious risk of publication bias. Elevated concentration of serum CA 19-9 is associated with poorer overall survival in patients with gastric cancer.

Keywords

Carbohydrate antigen 19-9 Gastric cancer Survival Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Polk DB, Peek Jr RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403–14.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98–107.PubMedCrossRefGoogle Scholar
  4. 4.
    Higuchi K, Tanabe S, Azuma M, Sasaki T, Ishido K, Koizumi W. Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status. Pathobiology. 2011;78:334–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1–48.PubMedCrossRefGoogle Scholar
  6. 6.
    Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2013;22:4–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK, Lee YC, Cheong JH, Hyung WJ, Noh SH, Kim CB: Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol 2013Google Scholar
  9. 9.
    Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Surgical resection of stage IV gastric cancer and prognosis. Anticancer Res. 2007;27:4381–6.PubMedGoogle Scholar
  10. 10.
    Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107:275–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Duraker N. Naci Celik A, Gencler N: The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. Eur J Surg Oncol. 2002;28:844–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 2001;32:41–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72–4 in gastric carcinoma. Tumour Biol. 2001;22:318–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  17. 17.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  18. 18.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  19. 19.
    Jo JC, Ryu MH, Koo DH, Ryoo BY, Kim HJ, Kim TW, Choi KD, Lee GH, Jung HY, Yook JH, Oh ST, Kim BS, Kim JH, Kang YK: Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol 2012Google Scholar
  20. 20.
    Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177–86.PubMedCrossRefGoogle Scholar
  21. 21.
    Liu X, Cai H, Wang Y. Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol. 2012;10:68.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105–10.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jiuchang Xiao
    • 1
  • Xiaoyan He
    • 2
  • Zengyan Wang
    • 3
  • Jiying Hu
    • 4
  • Fang Sun
    • 4
  • Feng Qi
    • 4
  • Shugang Yang
    • 5
  • Zhenyu Xiao
    • 2
  1. 1.Department of Clinical LaboratoryPeople’s Hospital of GanzhouGanzhouChina
  2. 2.Department of OncologyPeople’s Hospital of GanzhouGanzhouChina
  3. 3.Surgical CenterZhucheng People’s HospitalZhuchengChina
  4. 4.Department of Obstetrics and GynecologyMaternal and Child Health Hospital of WeifangWeifangChina
  5. 5.General and Hepatobiliary SurgeryZhucheng People’s HospitalZhuchengChina

Personalised recommendations